Intrinsic value of Spectrum Pharmaceuticals - SPPI

Previous Close

$19.03

  Intrinsic Value

$0.54

stock screener

  Rating & Target

str. sell

-97%

Previous close

$19.03

 
Intrinsic value

$0.54

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of SPPI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -10.43
  9.10
  8.69
  8.32
  7.99
  7.69
  7.42
  7.18
  6.96
  6.76
  6.59
  6.43
  6.29
  6.16
  6.04
  5.94
  5.84
  5.76
  5.68
  5.62
  5.55
  5.50
  5.45
  5.40
  5.36
  5.33
  5.29
  5.26
  5.24
  5.21
  5.19
Revenue, $m
  146
  159
  173
  188
  203
  218
  234
  251
  269
  287
  306
  325
  346
  367
  389
  412
  436
  462
  488
  515
  544
  574
  605
  638
  672
  708
  745
  784
  825
  868
  914
Variable operating expenses, $m
 
  198
  216
  233
  252
  271
  291
  312
  333
  356
  379
  402
  427
  453
  481
  509
  539
  570
  602
  636
  671
  708
  747
  787
  829
  874
  920
  968
  1,019
  1,072
  1,128
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  208
  198
  216
  233
  252
  271
  291
  312
  333
  356
  379
  402
  427
  453
  481
  509
  539
  570
  602
  636
  671
  708
  747
  787
  829
  874
  920
  968
  1,019
  1,072
  1,128
Operating income, $m
  -62
  -39
  -42
  -46
  -49
  -53
  -57
  -61
  -65
  -69
  -74
  -76
  -81
  -86
  -91
  -97
  -102
  -108
  -114
  -121
  -128
  -135
  -142
  -150
  -158
  -166
  -175
  -184
  -194
  -204
  -214
EBITDA, $m
  -36
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -21
  -22
  -24
  -25
  -27
  -28
  -30
  -32
  -33
  -35
  -37
  -39
  -42
  -44
  -46
  -49
  -51
  -54
  -57
  -60
  -63
  -66
Interest expense (income), $m
  3
  3
  4
  5
  5
  6
  7
  7
  8
  9
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  22
  23
  25
  26
  28
  29
  31
  33
  35
  37
Earnings before tax, $m
  -71
  -43
  -46
  -50
  -55
  -59
  -64
  -68
  -73
  -78
  -83
  -87
  -93
  -99
  -105
  -111
  -118
  -125
  -132
  -140
  -148
  -156
  -165
  -174
  -184
  -194
  -204
  -215
  -227
  -239
  -251
Tax expense, $m
  -2
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -69
  -43
  -46
  -50
  -55
  -59
  -64
  -68
  -73
  -78
  -83
  -87
  -93
  -99
  -105
  -111
  -118
  -125
  -132
  -140
  -148
  -156
  -165
  -174
  -184
  -194
  -204
  -215
  -227
  -239
  -251

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  158
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  429
  296
  321
  348
  376
  405
  435
  466
  498
  532
  567
  603
  641
  681
  722
  765
  810
  856
  905
  956
  1,009
  1,064
  1,122
  1,183
  1,246
  1,313
  1,382
  1,455
  1,531
  1,611
  1,695
Adjusted assets (=assets-cash), $m
  271
  296
  321
  348
  376
  405
  435
  466
  498
  532
  567
  603
  641
  681
  722
  765
  810
  856
  905
  956
  1,009
  1,064
  1,122
  1,183
  1,246
  1,313
  1,382
  1,455
  1,531
  1,611
  1,695
Revenue / Adjusted assets
  0.539
  0.537
  0.539
  0.540
  0.540
  0.538
  0.538
  0.539
  0.540
  0.539
  0.540
  0.539
  0.540
  0.539
  0.539
  0.539
  0.538
  0.540
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
  0.539
Average production assets, $m
  178
  194
  211
  228
  246
  265
  285
  305
  327
  349
  372
  396
  420
  446
  473
  501
  531
  561
  593
  626
  661
  698
  736
  775
  817
  860
  906
  954
  1,004
  1,056
  1,111
Working capital, $m
  151
  -8
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -25
  -26
  -28
  -29
  -31
  -32
  -34
  -36
  -38
  -40
  -42
  -44
Total debt, $m
  97
  114
  133
  152
  172
  192
  213
  236
  259
  283
  308
  334
  361
  389
  418
  449
  480
  514
  548
  585
  622
  662
  703
  746
  791
  839
  888
  940
  994
  1,051
  1,111
Total liabilities, $m
  193
  210
  229
  248
  268
  288
  309
  332
  355
  379
  404
  430
  457
  485
  514
  545
  576
  610
  644
  681
  718
  758
  799
  842
  887
  935
  984
  1,036
  1,090
  1,147
  1,207
Total equity, $m
  236
  85
  93
  100
  108
  117
  125
  134
  144
  153
  163
  174
  185
  196
  208
  220
  233
  247
  261
  275
  291
  307
  323
  341
  359
  378
  398
  419
  441
  464
  488
Total liabilities and equity, $m
  429
  295
  322
  348
  376
  405
  434
  466
  499
  532
  567
  604
  642
  681
  722
  765
  809
  857
  905
  956
  1,009
  1,065
  1,122
  1,183
  1,246
  1,313
  1,382
  1,455
  1,531
  1,611
  1,695
Debt-to-equity ratio
  0.411
  1.340
  1.430
  1.510
  1.590
  1.650
  1.710
  1.760
  1.800
  1.850
  1.880
  1.920
  1.950
  1.980
  2.010
  2.040
  2.060
  2.080
  2.100
  2.120
  2.140
  2.160
  2.180
  2.190
  2.200
  2.220
  2.230
  2.240
  2.250
  2.270
  2.280
Adjusted equity ratio
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288
  0.288

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -69
  -43
  -46
  -50
  -55
  -59
  -64
  -68
  -73
  -78
  -83
  -87
  -93
  -99
  -105
  -111
  -118
  -125
  -132
  -140
  -148
  -156
  -165
  -174
  -184
  -194
  -204
  -215
  -227
  -239
  -251
Depreciation, amort., depletion, $m
  26
  28
  30
  32
  35
  37
  40
  43
  45
  48
  51
  53
  56
  60
  63
  67
  71
  75
  79
  84
  88
  93
  98
  103
  109
  115
  121
  127
  134
  141
  148
Funds from operations, $m
  -57
  -15
  -17
  -18
  -20
  -22
  -24
  -26
  -28
  -30
  -32
  -34
  -37
  -39
  -42
  -45
  -47
  -50
  -53
  -57
  -60
  -63
  -67
  -71
  -75
  -79
  -83
  -88
  -93
  -98
  -103
Change in working capital, $m
  -17
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Cash from operations, $m
  -40
  -14
  -16
  -18
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -36
  -38
  -41
  -43
  -46
  -49
  -52
  -55
  -59
  -62
  -66
  -69
  -73
  -77
  -82
  -86
  -91
  -96
  -101
Maintenance CAPEX, $m
  0
  -24
  -26
  -28
  -30
  -33
  -35
  -38
  -41
  -44
  -46
  -50
  -53
  -56
  -60
  -63
  -67
  -71
  -75
  -79
  -84
  -88
  -93
  -98
  -103
  -109
  -115
  -121
  -127
  -134
  -141
New CAPEX, $m
  0
  -16
  -17
  -18
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -33
  -35
  -36
  -38
  -40
  -42
  -44
  -46
  -48
  -50
  -52
  -55
Cash from investing activities, $m
  -1
  -40
  -43
  -46
  -48
  -52
  -55
  -58
  -62
  -66
  -69
  -74
  -78
  -82
  -87
  -91
  -96
  -102
  -107
  -112
  -119
  -124
  -131
  -138
  -145
  -153
  -161
  -169
  -177
  -186
  -196
Free cash flow, $m
  -41
  -54
  -59
  -63
  -68
  -73
  -78
  -83
  -89
  -95
  -101
  -107
  -113
  -120
  -127
  -135
  -142
  -150
  -159
  -168
  -177
  -186
  -197
  -207
  -218
  -230
  -242
  -255
  -268
  -282
  -297
Issuance/(repayment) of debt, $m
  -9
  17
  18
  19
  20
  21
  21
  22
  23
  24
  25
  26
  27
  28
  29
  31
  32
  33
  35
  36
  38
  39
  41
  43
  45
  47
  49
  52
  54
  57
  60
Issuance/(repurchase) of shares, $m
  73
  50
  54
  58
  63
  67
  72
  77
  82
  88
  94
  98
  104
  110
  117
  124
  131
  139
  146
  155
  163
  172
  182
  192
  202
  213
  224
  236
  249
  262
  275
Cash from financing (excl. dividends), $m  
  60
  67
  72
  77
  83
  88
  93
  99
  105
  112
  119
  124
  131
  138
  146
  155
  163
  172
  181
  191
  201
  211
  223
  235
  247
  260
  273
  288
  303
  319
  335
Total cash flow (excl. dividends), $m
  18
  13
  14
  14
  15
  15
  16
  16
  17
  17
  18
  17
  17
  18
  19
  20
  20
  21
  22
  23
  24
  25
  27
  28
  29
  30
  32
  33
  35
  37
  38
Retained Cash Flow (-), $m
  -23
  -50
  -54
  -58
  -63
  -67
  -72
  -77
  -82
  -88
  -94
  -98
  -104
  -110
  -117
  -124
  -131
  -139
  -146
  -155
  -163
  -172
  -182
  -192
  -202
  -213
  -224
  -236
  -249
  -262
  -275
Prev. year cash balance distribution, $m
 
  158
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  121
  -40
  -44
  -48
  -52
  -57
  -61
  -66
  -71
  -76
  -81
  -86
  -92
  -98
  -104
  -111
  -117
  -124
  -131
  -139
  -147
  -155
  -164
  -173
  -182
  -192
  -203
  -214
  -225
  -237
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  116
  -37
  -38
  -40
  -41
  -41
  -41
  -41
  -41
  -40
  -38
  -37
  -35
  -33
  -31
  -28
  -26
  -23
  -20
  -18
  -15
  -13
  -11
  -9
  -7
  -6
  -4
  -3
  -2
  -2
Current shareholders' claim on cash, %
  100
  92.8
  86.1
  80.0
  74.3
  69.0
  64.2
  59.7
  55.5
  51.6
  48.0
  44.7
  41.7
  38.9
  36.2
  33.8
  31.5
  29.3
  27.4
  25.5
  23.8
  22.2
  20.7
  19.3
  18.0
  16.7
  15.6
  14.6
  13.6
  12.7
  11.8

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

FINANCIAL RATIOS  of  Spectrum Pharmaceuticals (SPPI)

Valuation Ratios
P/E Ratio -22.2
Price to Sales 10.5
Price to Book 6.5
Price to Tangible Book
Price to Cash Flow -38.3
Price to Free Cash Flow -38.3
Growth Rates
Sales Growth Rate -10.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 41.1%
Total Debt to Equity 41.1%
Interest Coverage -23
Management Effectiveness
Return On Assets -15.6%
Ret/ On Assets - 3 Yr. Avg. -11.6%
Return On Total Capital -21.4%
Ret/ On T. Cap. - 3 Yr. Avg. -16.5%
Return On Equity -30.7%
Return On Equity - 3 Yr. Avg. -23.2%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 76%
Gross Margin - 3 Yr. Avg. 81.5%
EBITDA Margin -28.8%
EBITDA Margin - 3 Yr. Avg. -15.5%
Operating Margin -42.5%
Oper. Margin - 3 Yr. Avg. -27.9%
Pre-Tax Margin -48.6%
Pre-Tax Margin - 3 Yr. Avg. -34.3%
Net Profit Margin -47.3%
Net Profit Margin - 3 Yr. Avg. -34.4%
Effective Tax Rate 2.8%
Eff/ Tax Rate - 3 Yr. Avg. -1.2%
Payout Ratio 0%

SPPI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SPPI stock intrinsic value calculation we used $146 million for the last fiscal year's total revenue generated by Spectrum Pharmaceuticals. The default revenue input number comes from 2016 income statement of Spectrum Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SPPI stock valuation model: a) initial revenue growth rate of 9.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for SPPI is calculated based on our internal credit rating of Spectrum Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Spectrum Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SPPI stock the variable cost ratio is equal to 124.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for SPPI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Spectrum Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Spectrum Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SPPI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SPPI are equal to 121.6%.

Life of production assets of 7.5 years is the average useful life of capital assets used in Spectrum Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SPPI is equal to -4.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $236 million for Spectrum Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 101.319 million for Spectrum Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Spectrum Pharmaceuticals at the current share price and the inputted number of shares is $1.9 billion.

RELATED COMPANIES Price Int.Val. Rating
SGEN Seattle Geneti 53.48 1.07  str.sell
CELG Celgene 102.65 35.78  str.sell
EGRX Eagle Pharmace 58.84 1,184.22  str.buy
PFE Pfizer 36.94 28.29  sell
RDY Dr. Reddy' 38.67 17.07  str.sell
MRK Merck&Co 61.28 30.23  sell
BMY Bristol-Myers 62.28 20.77  str.sell

COMPANY NEWS

▶ The 10 Best Stocks of 2017   [Jan-08-18 06:03AM  Motley Fool]
▶ Top 4 Small-Cap Stocks for 2018   [Jan-05-18 09:55AM  Investopedia]
▶ Spectrum Pharmaceuticals Announces Leadership Changes   [Dec-17-17 06:59PM  Business Wire]
▶ Chart in Focus: Spectrum Pharmaceuticals Financials   [Dec-12-17 10:32AM  Market Realist]
▶ A Look at Spectrum Pharmaceuticals Recent Acquisitions   [Dec-11-17 05:10PM  Market Realist]
▶ 3 Biotech Stocks to Be Thankful for This Year   [Nov-19-17 11:43AM  Motley Fool]
▶ Top 4 Small-Cap Stocks for 2017   [Nov-06-17 11:59AM  Investopedia]
▶ Spectrum Pharma reports 3Q loss   [Nov-02-17 05:33PM  Associated Press]
▶ Harry Boxers three biotech-stock breakouts to watch   [Oct-26-17 04:15PM  MarketWatch]
▶ What Happened in the Stock Market Today   [Oct-18-17 05:04PM  Motley Fool]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Sep-30-17 10:34AM  Motley Fool]
▶ Evomelas Market Share Is Increasing in 2017   [Sep-01-17 10:38AM  Market Realist]
▶ Why Spectrum Pharmaceuticals Stock Is Sinking Today   [May-03-17 01:04PM  Motley Fool]
▶ Spectrum Pharma reports 1Q loss   [May-02-17 06:06PM  Associated Press]
Financial statements of SPPI
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.